FTLF FITLIFE BRANDS, INC.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1374328 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.5%
TTM net income YoY1.9%
TTM EPS YoY1.5%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR17.1%
Margins
Gross margin36.7%
Operating margin11.0%
Net margin6.7%
FCF margin4.5%
EBITDA margin11.9%
Returns
ROE15.1%
ROA6.4%
ROIC (approx.)13.8%
Asset turnover0.96x
Leverage & solvency
Liabilities / assets53.3%
Debt / equity0.00x
Current ratio1.64x
Interest coverage3.93x
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio2.0%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $25.62M | $26.55M | $25.32M | $25.91M | $23.48M | $16.13M | $15.94M | $15.01M |
| Cost of revenue | $15.95M | $16.74M | $15.81M | $16.97M | $14.75M | $9.22M | $9.06M | $8.80M |
| Gross profit | $9.67M | $9.81M | $9.52M | $8.94M | $8.74M | $6.90M | $6.87M | $6.21M |
| SG&A expense | $5.18M | $4.75M | $4.96M | $4.93M | $4.11M | $2.48M | $2.51M | $2.29M |
| Operating income | $2.65M | $3.35M | $3.06M | $2.27M | $2.32M | $2.52M | $2.96M | $2.88M |
| Interest expense | $654,000 | $679,000 | $735,000 | $814,000 | $562,000 | $175,000 | $244,000 | $282,000 |
| Pretax income | $2.04M | $2.68M | $2.35M | $1.38M | $1.75M | $2.38M | $2.72M | $2.65M |
| Income tax | $465,000 | $734,000 | $627,000 | -$258,000 | $829,000 | $631,000 | $701,000 | $581,000 |
| Net income | $1.57M | $1.95M | $1.72M | $1.64M | $921,000 | $1.75M | $2.02M | $2.07M |
| EBITDA | $2.90M | $3.61M | $3.31M | $2.52M | $2.45M | $2.53M | $2.98M | $2.90M |
| EPS (basic) | 0.17 | 0.21 | 0.18 | — | 0.10 | 0.19 | 0.22 | — |
| EPS (diluted) | 0.16 | 0.20 | 0.17 | — | 0.09 | 0.18 | 0.20 | — |
| Weighted avg. shares (diluted) | 9.91M | 9.91M | 9.99M | — | 10.00M | 9.96M | 9.93M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $689,000 | $1.09M | $1.19M | $1.65M | $3.51M | $1.53M | $5.94M | $4.47M |
| Receivables | $8.05M | $6.98M | $7.78M | $8.77M | $9.64M | $2.49M | $2.69M | $1.63M |
| Inventory | $22.74M | $21.07M | $21.53M | $21.32M | $22.23M | $11.72M | $12.13M | $11.07M |
| Current assets | $33.62M | $30.55M | $31.64M | $33.07M | $37.40M | $22.18M | $21.76M | $18.14M |
| PP&E, net | $52,000 | $78,000 | $106,000 | $128,000 | $135,000 | $81,000 | $89,000 | $75,000 |
| Goodwill | $19.33M | $19.33M | $19.36M | $19.39M | $19.37M | $13.12M | $13.04M | $13.02M |
| Intangibles | $50.73M | $50.95M | $51.20M | $51.44M | $51.65M | $26.29M | $26.23M | $26.23M |
| Total assets | $105.38M | $102.59M | $104.27M | $106.32M | $109.98M | $62.85M | $62.19M | $58.53M |
| Current liabilities | $20.55M | $20.91M | $20.81M | $21.61M | $33.02M | $12.97M | $13.30M | $11.31M |
| Short-term debt | — | — | — | — | $14.09M | — | — | $4.50M |
| Long-term debt | — | — | — | — | $32.36M | $6.32M | $7.44M | $8.55M |
| Total debt | — | — | — | — | $46.46M | $6.32M | $7.44M | $13.05M |
| Total liabilities | $56.12M | $55.22M | $58.89M | $62.68M | $68.09M | $21.93M | $23.27M | $22.41M |
| Shareholders' equity | $49.25M | $47.37M | $45.38M | $43.64M | $41.89M | $40.92M | $38.92M | $36.13M |
| Net debt | — | — | — | — | $42.95M | $4.79M | $1.50M | $8.58M |
| Shares outstanding | 9.39M | 9.39M | 9.39M | 9.39M | 9.39M | 9.39M | 9.38M | 9.21M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.67M | $3.63M | $2.48M | $244,000 | $3.67M | $1.20M | $2.33M | $957,000 |
| Capital expenditure | $0 | $0 | $0 | $5,000 | $8,000 | $5,000 | $24,000 | $0 |
| Free cash flow | -$1.67M | $3.63M | $2.48M | $239,000 | $3.66M | $1.19M | $2.30M | $957,000 |
| Investing cash flow | $0 | $0 | $0 | -$5,000 | -$37.51M | -$5.00M | -$24,000 | $0 |
| Financing cash flow | $1.28M | -$3.72M | -$2.92M | -$1.92M | $35.58M | -$702,000 | -$866,000 | -$1.11M |
| Depreciation & amortization | $250,000 | $252,000 | $248,000 | $251,000 | $136,000 | $14,000 | $19,000 | $23,000 |
| Stock-based compensation | — | — | $17,000 | — | — | — | $107,000 | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.